These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 14633703)

  • 1. The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells.
    Xu W; Yuan X; Jung YJ; Yang Y; Basso A; Rosen N; Chung EJ; Trepel J; Neckers L
    Cancer Res; 2003 Nov; 63(22):7777-84. PubMed ID: 14633703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.
    Solit DB; Basso AD; Olshen AB; Scher HI; Rosen N
    Cancer Res; 2003 May; 63(9):2139-44. PubMed ID: 12727831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.
    Lenferink AE; Busse D; Flanagan WM; Yakes FM; Arteaga CL
    Cancer Res; 2001 Sep; 61(17):6583-91. PubMed ID: 11522658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of Hsp90 inhibition on protein kinases regulating signal transduction pathways required for myoblast differentiation.
    Yun BG; Matts RL
    Exp Cell Res; 2005 Jul; 307(1):212-23. PubMed ID: 15922741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest.
    Srethapakdi M; Liu F; Tavorath R; Rosen N
    Cancer Res; 2000 Jul; 60(14):3940-6. PubMed ID: 10919672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
    Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
    Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.
    Xia W; Mullin RJ; Keith BR; Liu LH; Ma H; Rusnak DW; Owens G; Alligood KJ; Spector NL
    Oncogene; 2002 Sep; 21(41):6255-63. PubMed ID: 12214266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
    Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
    Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription.
    Bonvini P; An WG; Rosolen A; Nguyen P; Trepel J; Garcia de Herreros A; Dunach M; Neckers LM
    Cancer Res; 2001 Feb; 61(4):1671-7. PubMed ID: 11245482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins.
    Shimamura T; Lowell AM; Engelman JA; Shapiro GI
    Cancer Res; 2005 Jul; 65(14):6401-8. PubMed ID: 16024644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hsp90 functions to balance the phosphorylation state of Akt during C2C12 myoblast differentiation.
    Yun BG; Matts RL
    Cell Signal; 2005 Dec; 17(12):1477-85. PubMed ID: 15935620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
    Pedersen NM; Breen K; Rødland MS; Haslekås C; Stang E; Madshus IH
    Mol Cancer Res; 2009 Feb; 7(2):275-84. PubMed ID: 19208749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis.
    Tan M; Li P; Klos KS; Lu J; Lan KH; Nagata Y; Fang D; Jing T; Yu D
    Cancer Res; 2005 Mar; 65(5):1858-67. PubMed ID: 15753384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B; Chang CM; Yuan M; McKenna WG; Shu HK
    Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level.
    Campiglio M; Locatelli A; Olgiati C; Normanno N; Somenzi G; Viganò L; Fumagalli M; Ménard S; Gianni L
    J Cell Physiol; 2004 Feb; 198(2):259-68. PubMed ID: 14603528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin.
    Bull EE; Dote H; Brady KJ; Burgan WE; Carter DJ; Cerra MA; Oswald KA; Hollingshead MG; Camphausen K; Tofilon PJ
    Clin Cancer Res; 2004 Dec; 10(23):8077-84. PubMed ID: 15585643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition.
    Dote H; Cerna D; Burgan WE; Camphausen K; Tofilon PJ
    Cancer Res; 2005 Aug; 65(15):6967-75. PubMed ID: 16061682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ubiquitination and downregulation of ErbB2 and estrogen receptor-alpha by kinase inhibitor MP-412 in human breast cancer cells.
    Suzuki T; Fujii A; Ochi H; Nakamura H
    J Cell Biochem; 2011 Sep; 112(9):2279-86. PubMed ID: 21503962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.
    Moasser MM; Basso A; Averbuch SD; Rosen N
    Cancer Res; 2001 Oct; 61(19):7184-8. PubMed ID: 11585753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.